Atreca to Participate at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology firm, will participate in several virtual investor conferences in March 2021. The schedule includes the Cowen 41st Annual Health Care Conference on March 1 at 1:20 p.m. EST discussing "Novel Oncology Targets," the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. EST, and the 33rd Annual Roth Conference on March 16 at 4:00 p.m. EDT. Live audio webcasts will be available on Atreca's website, with replays archived for 90 days.

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

Cowen 41st Annual Health Care Conference
Date: Monday, March 1, 2021
Panel discussion time: 1:20 p.m. EST
Title: “Novel Oncology Targets”

H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Presentation time: 7:00 a.m. EST

33^rd Annual Roth Conference
Date: Tuesday, March 16, 2021
Fireside chat time: 4:00 p.m. EDT

A live audio webcast of the H.C. Wainwright and Roth presentations can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of both presentations will be available on the Company's website for 90 days following the live event.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com

Source: Atreca, Inc.

FAQ

What is Atreca's schedule for the Cowen 41st Annual Health Care Conference in 2021?

Atreca will participate in the Cowen 41st Annual Health Care Conference on March 1, 2021, at 1:20 p.m. EST.

When will Atreca present at the H.C. Wainwright Global Life Sciences Conference in 2021?

Atreca's presentation at the H.C. Wainwright Global Life Sciences Conference is scheduled for March 9, 2021, at 7:00 a.m. EST.

What time is the Atreca fireside chat at the 33rd Annual Roth Conference?

Atreca's fireside chat at the 33rd Annual Roth Conference will occur on March 16, 2021, at 4:00 p.m. EDT.

Where can I find the live webcasts of Atreca's presentations?

Live audio webcasts of Atreca's presentations will be available on the Events & Presentations section of their website.

How long will the replays of Atreca's presentations be available?

Archived replays of Atreca's presentations will be accessible for 90 days after the live events.